Skip to main navigation
Harrow Health

> Main Menu

About Our Company Our History Our Mission, Vision, Values Our Leadership
Integrity
Contact
Investors Overview News Events Letters to Stockholders Corporate Transparency Report Corporate Governance SEC Filings & Financials Stock Information Investor Resources

> Main Menu

About
Our Company Our History Our Mission, Vision, Values Our Leadership
Integrity Contact
Investors
Overview News Events Letters to Stockholders Corporate Transparency Report Corporate Governance SEC Filings & Financials Stock Information Investor Resources

Press Releases

May 5, 2022
Harrow Health Announces First Quarter 2022 Financial Results
May 4, 2022
Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation
April 22, 2022
Harrow Health to Participate in B. Riley Securities’ Annual Neuro & Ophthalmology Investor Conference
April 20, 2022
Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022
March 31, 2022
Harrow Health Announces Appointments to Its Board of Directors
March 10, 2022
Harrow Health Announces Fourth Quarter and Year-End 2021 Financial Results
March 10, 2022
Melt Pharmaceuticals Names Experienced Executive Brad Osborne as Chief Financial Officer
February 24, 2022
Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022
February 22, 2022
Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100
February 15, 2022
Harrow Health to Present at Aegis Virtual Conference

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 13
Harrow Health

Address

102 Woodmont Blvd., Suite 610
Nashville, TN 37205

Phone

(615) 733 4730
(615) 733 4737 (Investor Relations)

Social

LinkedIn

© 2022 Harrow Health, Inc.

> Footer

Privacy Policy Cookie Notice